

## Memphasys Commences Felix™ System Utilisation Testing in China Under Agreement with Heranova

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce the commencement of in vitro utilisation testing of its Felix™ System in China, as part of the agreement with Heranova Lifesciences HK Limited (“Heranova”), a Hong Kong-based biotech company specialising in women’s health<sup>1</sup>.

The in vitro utilisation testing, conducted at Sichuan Jinxin Xinan Women & Children Hospital (Bisheng) in Chengdu, China, marks a significant step towards validating the usability and clinical applicability of the Felix™ System in one of the world’s largest assisted reproductive treatment markets.

### Utilisation Testing Overview

Under the agreement, Heranova will lead the testing to assess the Felix™ System’s usability across both routine and challenging in vitro fertilisation (IVF) cases.

- **Test Location:** Sichuan Jinxin Xinan Women & Children Hospital (Bisheng), Chengdu, Sichuan, China.
- **Patient Sample:** 50 cases (routine and challenging).
- **Equipment Provided:** Memphasys has supplied 50 Felix™ cartridges and one Felix™ console.

### Test Endpoints

The utilisation testing will evaluate both the biological performance of the Felix™ System, and its health economic benefits.

#### 1. In Vitro Product Measurements

These endpoints will assess the ability of the Felix™ System to improve key sperm parameters, which are critical for successful fertilisation and embryo development in IVF treatments:

- **Total Motility (%):** Determines the percentage of sperm capable of active movement, essential for successful fertilisation.
- **Sperm Morphology (%):** Assesses the proportion of sperm with normal shape and structure, which impacts their ability to fertilise an egg.
- **Spermatozoa Concentration (millions/mL):** Measures the density of sperm in a given sample, providing insight into the effectiveness of sperm enrichment.
- **Progressive Motility (%):** Focuses on the percentage of sperm moving in a straight line or with purposeful motion, a key indicator of fertility potential.

<sup>1</sup> Refer ASX announcement dated 12 December 2024

- **DNA Fragmentation:** Evaluates the integrity of sperm DNA, a vital factor for embryo quality and successful pregnancy. While DNA fragmentation analysis is subject to associated costs, its inclusion provides comprehensive insights into the Felix™ System's capability to optimise sperm quality.

## 2. Health Economic Objectives

In addition to biological performance, the test will explore the Felix™ System's operational and usability advantages, which are critical for adoption in high-volume fertility clinics:

- **Non-Clinical Operating Costs:** The test will compare the time and resource requirements of the Felix™ System with traditional methods, focusing on:
  - Procedure efficiency: Time taken to process sperm samples.
  - Resource utilisation: Reduction in consumables and staff workload.
  - Overall cost savings: Potential reduction in clinic expenses associated with sperm preparation.
- **Usability:** The ease of use and operator satisfaction of the Felix™ System will be assessed, highlighting:
  - **User Training Requirements:** Simplicity and time needed for staff to become proficient with the Felix™ System.
  - **Operational Workflow:** Integration of the Felix™ System into existing IVF clinic processes without disruption.
  - **Operator Feedback:** Collection of user opinions on system design, handling, and overall satisfaction.

These endpoints aim to demonstrate that the Felix™ System not only enhances sperm quality, but also delivers significant economic and operational benefits, making it a compelling choice for fertility clinics.

### Strategic Significance

The results of this testing will be pivotal in demonstrating the Felix™ System's advantages in sperm selection for IVF, potentially paving the way for expanded clinical use in the Greater China market. Heranova's expertise in the region and the system's advanced bio-separation technology align to address the growing demand for effective reproductive healthcare solutions.

**Commenting on the Testing Dr. David Ali, Managing Director & CEO of Memphasys, said:**

"The commencement of utilisation testing with Heranova represents a critical step in establishing the Felix™ System's presence in Greater China. This milestone reinforces our commitment to bringing innovative solutions to global markets while leveraging Heranova's expertise to navigate the local landscape effectively."

**Dr. Frank Zhang, VP of Medical at Heranova, added:**

"The Felix™ System aligns perfectly with our mission to advance reproductive health. This testing will

validate its potential to enhance patient outcomes and streamline fertility clinic operations across the region.”

### **IVF Market Opportunity in China**

China’s IVF market, valued at USD 5.37 billion in 2023, is projected to grow to USD 9.04 billion by 2030 at a CAGR of 7.7%, driven by factors such as delayed motherhood, rising infertility rates, and advancements in reproductive technologies. Memphasys is well-positioned to capture this growth through the Felix™ System’s innovative capabilities.

This announcement has been approved for release by the Board of Memphasys Limited.

**ENDS**

### **For further information, please contact:**

Dr David Ali  
Managing Director & CEO  
Memphasys Limited  
Tel: +61 2 8415 7300  
E: [david.ali@memphasys.com](mailto:david.ali@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors  
Tel: +61 433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

### **About Memphasys**

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio separation technology, utilised by the Company’s most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: [www.memphasys.com](http://www.memphasys.com)

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.